Coagulation Disorder’s in SARS-CoV-2 Patients
| Author | Akram Aghaamini Fashami | en |
| Author | Mahtab Sayadi | en |
| Author | Ebrahim Miri Moghaddam | en |
| Orcid | Akram Aghaamini Fashami [0000-0003-0428-6379] | en |
| Orcid | Mahtab Sayadi [0000-0003-3087-705X] | en |
| Orcid | Ebrahim Miri Moghaddam [0000-0001-9435-2450] | en |
| Issued Date | 2023-01-31 | en |
| Abstract | Context: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease of 2019 (COVID-19). Pulmonary manifestations have been identified as the common symptom, and patients present a wide range of hematologic changes depending on the flow of the diseases. The interpretation and treatment of hematological complications in COVID-19 patients are very challenging. There are limited guidelines thus far due to the novelty of the disease. Evidence Acquisition: This review summarizes the hematological findings (platelet and coagulation/fibrinolytic) in COVID-19 patients and discusses possible mechanisms for their changes. Results: The results showed that the common findings were thrombocytopenia, elevated D-dimer levels, and prolonged prothrombin time (PT) and partial thromboplastin time (PTT) in severe patients. Conclusions: Attention to hematological changes may be helpful biomarkers in diagnosing and determining patients needing intensive care, as well as monitoring the treatment process and treatment effects on COVID-19 patients. | en |
| DOI | https://doi.org/10.5812/zjrms-121045 | en |
| Keyword | COVID-19 | en |
| Keyword | Laboratory Hematology | en |
| Keyword | Platelet | en |
| Keyword | Coagulation Factor | en |
| Publisher | Brieflands | en |
| Title | Coagulation Disorder’s in SARS-CoV-2 Patients | en |
| Type | Review Article | en |